A Trial Study of Akkermansia muciniphila on Improving Sensitivity to Antihypertensive Drugs in Patients with Refractory Hypertension

Akkermansia muciniphila improves antihypertensive drug sensitivity in patients with refractory hypertension

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2400093598

Enrollment

Unknown

Registered

2024-12-09

Start date

2024-12-31

Completion date

Unknown

Last updated

2024-12-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Refractory hypertension

Interventions

Patients with Refractory Hypertension:The patient supplemented with Akkermansia muctophila probiotic supplements for one month.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: The inclusion criteria of the refractory hypertension group are in accordance with the 2020 edition of the Chinese Guidelines for the Diagnosis and Treatment of Refractory Hypertension: on the basis of lifestyle improvement, the blood pressure cannot be controlled below 140/90mmHg with three or more antihypertensive drugs (including one diuretic) in sufficient dosage and with reasonable combination.

Exclusion criteria

Exclusion criteria: 1) Malignant tumors, severe systemic infectious diseases, hematologic diseases, and history of organ transplantation; 2) severe heart failure, hyperthyroidism, hypothyroidism, etc.; 3) severe liver and kidney dysfunction, etc.

Design outcomes

Primary

Measure	Time frame
Blood pressure ;Intestinal flora;	—

Countries

China

Contacts

Public ContactYongtai Gong

The first Afiliated Hospital of Harbin Medical University

gongth@126.com+86 159 4518 1294

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026